Episode Details

Novo Nordisk’s shares slimmed way down as investors felt disappointed by its latest obesity drug trial, while Oura raised $200 million from investors – proving it’s not just celebrities and executives who adore the Finnish smart rings.

Today’s stories:

• Novo Nordisk’s Stock Went On A Crash Diet After The Firm’s Latest Clinical Trial
• Investors Demonstrated Their Love For Oura, Lifting The Smart Ring Brand’s Valuation

Try Finimize Pro